PT3914736T - Deteção de cancro, tecido do cancro de origem e/ou um tipo de celula de cancro - Google Patents

Deteção de cancro, tecido do cancro de origem e/ou um tipo de celula de cancro

Info

Publication number
PT3914736T
PT3914736T PT207103326T PT20710332T PT3914736T PT 3914736 T PT3914736 T PT 3914736T PT 207103326 T PT207103326 T PT 207103326T PT 20710332 T PT20710332 T PT 20710332T PT 3914736 T PT3914736 T PT 3914736T
Authority
PT
Portugal
Prior art keywords
cancer
origin
cell type
detecting
tissue
Prior art date
Application number
PT207103326T
Other languages
English (en)
Original Assignee
Grail Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grail Inc filed Critical Grail Inc
Publication of PT3914736T publication Critical patent/PT3914736T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6832—Enhancement of hybridisation reaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2523/00—Reactions characterised by treatment of reaction samples
    • C12Q2523/10—Characterised by chemical treatment
    • C12Q2523/125—Bisulfite(s)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/204—Modifications characterised by specific length of the oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2535/00—Reactions characterised by the assay type for determining the identity of a nucleotide base or a sequence of oligonucleotides
    • C12Q2535/122—Massive parallel sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Data Mining & Analysis (AREA)
  • Epidemiology (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Software Systems (AREA)
  • Bioethics (AREA)
  • Evolutionary Computation (AREA)
  • Artificial Intelligence (AREA)
  • Databases & Information Systems (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
PT207103326T 2019-01-25 2020-01-24 Deteção de cancro, tecido do cancro de origem e/ou um tipo de celula de cancro PT3914736T (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962797174P 2019-01-25 2019-01-25
US201962797170P 2019-01-25 2019-01-25
US201962797176P 2019-01-25 2019-01-25

Publications (1)

Publication Number Publication Date
PT3914736T true PT3914736T (pt) 2024-03-27

Family

ID=69780286

Family Applications (1)

Application Number Title Priority Date Filing Date
PT207103326T PT3914736T (pt) 2019-01-25 2020-01-24 Deteção de cancro, tecido do cancro de origem e/ou um tipo de celula de cancro

Country Status (14)

Country Link
US (2) US20220119890A1 (pt)
EP (2) EP4353834A3 (pt)
CN (1) CN113728115A (pt)
AU (1) AU2020212057A1 (pt)
CA (1) CA3127762A1 (pt)
DK (1) DK3914736T3 (pt)
ES (1) ES2974178T3 (pt)
FI (1) FI3914736T3 (pt)
IL (1) IL285126A (pt)
LT (1) LT3914736T (pt)
PL (1) PL3914736T3 (pt)
PT (1) PT3914736T (pt)
SI (1) SI3914736T1 (pt)
WO (1) WO2020154682A2 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019195268A2 (en) 2018-04-02 2019-10-10 Grail, Inc. Methylation markers and targeted methylation probe panels
WO2020069350A1 (en) 2018-09-27 2020-04-02 Grail, Inc. Methylation markers and targeted methylation probe panel
AU2020217719A1 (en) * 2019-02-05 2021-08-19 Grail, Llc Detecting cancer, cancer tissue of origin, and/or a cancer cell type
WO2020237184A1 (en) 2019-05-22 2020-11-26 Grail, Inc. Systems and methods for determining whether a subject has a cancer condition using transfer learning
GB2627085A (en) 2019-11-06 2024-08-14 Univ Leland Stanford Junior Methods and systems for analysing nucleic acid molecules
CA3159651A1 (en) 2019-12-18 2021-06-24 Jing Xiang Systems and methods for estimating cell source fractions using methylation information
EP4111455A1 (en) 2020-02-28 2023-01-04 Grail, LLC Systems and methods for calling variants using methylation sequencing data
US20210292845A1 (en) 2020-02-28 2021-09-23 Grail, Inc. Identifying methylation patterns that discriminate or indicate a cancer condition
US20210358626A1 (en) 2020-03-04 2021-11-18 Grail, Inc. Systems and methods for cancer condition determination using autoencoders
CA3207988A1 (en) * 2021-04-06 2022-10-13 Oliver Claude VENN Conditional tissue of origin return for localization accuracy
CN117858954A (zh) * 2021-04-21 2024-04-09 赫利奥健康公司 细胞异质性调整的克隆甲基化(chalm)：甲基化定量方法
US11783912B2 (en) 2021-05-05 2023-10-10 The Board Of Trustees Of The Leland Stanford Junior University Methods and systems for analyzing nucleic acid molecules
IL310649A (en) 2021-08-05 2024-04-01 Grail Llc Emergence of a somatic variant together with abnormal methylated segments
EP4299764A1 (en) * 2022-06-28 2024-01-03 Universal Diagnostics, S.A. Methods for detecting pancreatic cancer using dna methylation markers
WO2024086226A1 (en) * 2022-10-19 2024-04-25 Grail, Llc Component mixture model for tissue identification in dna samples

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010037001A2 (en) 2008-09-26 2010-04-01 Immune Disease Institute, Inc. Selective oxidation of 5-methylcytosine by tet-family proteins
WO2011127136A1 (en) 2010-04-06 2011-10-13 University Of Chicago Composition and methods related to modification of 5-hydroxymethylcytosine (5-hmc)
US20150259743A1 (en) * 2013-12-31 2015-09-17 Roche Nimblegen, Inc. Methods of assessing epigenetic regulation of genome function via dna methylation status and systems and kits therefor
CA2938451C (en) 2014-01-30 2023-10-17 The Regents Of The University Of California Methylation haplotyping for non-invasive diagnosis (monod)
ES2812753T3 (es) * 2014-03-31 2021-03-18 Mayo Found Medical Education & Res Detección de neoplasma colorectal
US9984201B2 (en) * 2015-01-18 2018-05-29 Youhealth Biotech, Limited Method and system for determining cancer status
GB201511152D0 (en) * 2015-06-24 2015-08-05 Ucl Business Plc Method of diagnosing bladder cancer
KR20190095410A (ko) * 2016-12-22 2019-08-14 가던트 헬쓰, 인크. 핵산 분자를 분석하기 위한 방법 및 시스템
EP3589371A4 (en) * 2017-03-02 2020-11-25 Youhealth Oncotech, Limited METHYLATION MARKERS FOR THE DIAGNOSIS OF HEPER CELL CARCINOMA AND LUNG CANCER
AU2019234843A1 (en) 2018-03-13 2020-09-24 Grail, Llc Anomalous fragment detection and classification

Also Published As

Publication number Publication date
FI3914736T3 (fi) 2024-03-19
EP3914736B1 (en) 2023-12-20
CA3127762A1 (en) 2020-07-30
WO2020154682A2 (en) 2020-07-30
IL285126A (en) 2021-09-30
LT3914736T (lt) 2024-06-10
ES2974178T3 (es) 2024-06-26
DK3914736T3 (da) 2024-03-25
SI3914736T1 (sl) 2024-05-31
EP4353834A2 (en) 2024-04-17
PL3914736T3 (pl) 2024-06-17
US20220090207A1 (en) 2022-03-24
AU2020212057A1 (en) 2021-08-26
CN113728115A (zh) 2021-11-30
US20220119890A1 (en) 2022-04-21
EP3914736A2 (en) 2021-12-01
WO2020154682A3 (en) 2020-10-01
EP4353834A3 (en) 2024-05-01

Similar Documents

Publication Publication Date Title
IL285126A (en) Detection of cancer, cancerous source tissue, and/or type of cancer cells
IL285316A (en) Cancer detection, the source of the cancer tissue and/or the type of cancer cells
EP3548994A4 (en) DETECTION AND USE OF ELECTRIC SIGNALS OF BODY TISSUES
EP4262267A4 (en) ENHANCED DETECTION PROCEDURE
IL299044A (en) Advanced ransomware detection
SG11202112963PA (en) Safe immuno-stealth cells
GB201903838D0 (en) Cardiac scar detection
IL290037A (en) Ergothioneine, s-methyl-ergothioneine and their uses
GB201905688D0 (en) Transition Detection
EP3631444A4 (en) BIOMARKERS AND PATIENT SELECTION STRATEGIES
EP3864165A4 (en) DETECTION OF AN ORIGINAL CANCER CELL
EP3836935A4 (en) TREATMENT OF B-CELL MALIGNOS
EP3655546A4 (en) TUMOR DETECTION AND MONITORING
EP4101379C0 (en) BIOSENSOR CAPSULE AND SYSTEM
GB202008412D0 (en) Electrode and garment
SG11202110729TA (en) Integrin alpha10 and aggressive cancer forms
GB201910299D0 (en) Medical uses, methods and uses
GB201915469D0 (en) Cancer detection methods
EP3143406A4 (en) Methionine aminopeptidase overexpression in the peripheral blood and peripheral blood mononuclear cells is a marker for colorectal cancer screening, diagnosis and prognosis
EP3701050C0 (en) DIAGNOSIS AND/OR PROGNOSIS OF HER2-DEPENDENT CANCER USING ONE OR MORE MIRNAS AS BIOMARKERS
GB202112225D0 (en) State or activity detection
EP3916111A4 (en) SETS OF UNIVERSAL PRIMERS FOR THE DETECTION OF FLAVIVIRUS AND THEIR USE
EP4048783C0 (en) MODIFIED CELL
GB202009403D0 (en) Electrochemical sensing
EP3687555A4 (en) TISSUE FACTOR TISSUE CAR-NK AND CAR-T-CELL THERAPY